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Objectives: This review aimed to better depict the clinical features and address the
issue of therapeutic management of Trichosporon deep-seated infections.
Methods: We comprehensively reviewed the cases of invasive Trichosporon infection
reported in the literature from 1994 (date of taxonomic modification) to 2015. Data from
antifungal susceptibility testing (AST) studies were also analyzed.
Results: Two hundred and three cases were retained and split into four groups:
homeopathy (n = 79), other immunodeficiency conditions (n = 41), miscellaneous
(n = 58) and newborns (n = 25). Trichosporon asahii was the main causative species
(46.7%) and may exhibit cross-resistance to different antifungal classes. The unfavorable
outcome rate was at 44.3%. By multivariate analysis, breakthrough infection (OR 2.45)
was associated with unfavorable outcome, whilst the use of an azole-based therapy
improved the prognosis (OR 0.16). Voriconazole-based treatment was associated with
favorable outcome in hematological patients (73.6 vs. 41.8%; p= 0.016). Compiled data
from AST demonstrated that (i) T. asahii exhibits the highest MICs to amphotericin B and
(ii) voriconazole has the best in vitro efficacy against clinical isolates of Trichosporon spp.
Conclusions: Trichosporon infection is not only restricted to hematological patients.
Analysis of compiled data from AST and clinical outcome support the use of voriconazole
as first line therapy.
Keywords: Trichosporon species, invasive infection, risk factors, prognosis, diagnosis, treatment, antifungal
resistance
INTRODUCTION
Trichosporon spp. are yeast-like organisms responsible for superficial infection (white piedra),
allergic pneumonitis and more rarely, invasive infection (Colombo et al., 2011). In the 1980’s,
Trichosporon invasive infections (ITI) were considered the secondmost common cause of fungemia
in patients with hematological malignancies (Walsh et al., 1986). However, as triazole derivatives,
such as fluconazole, became available, the incidence of those infections decreased (Kaufman et al.,
2001; Gomes et al., 2014). On the contrary, maybe due to the breakthrough of the echinocandins,
now considered as drugs of choice in many clinical contexts at high-risk for invasive fungal
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infection (IFI), we now deal with a reemergence of this difficult
to manage pathogen (Liao et al., 2015). Indeed, the diagnosis
of these infections is difficult to anticipate, largely due to the
lack of a specific biomarker assay. In addition, identification
at the species level is sometimes confusing since the in-depth
taxonomic revision of the genus proposed in 1994 (Guého
et al., 1994). From then, molecular analyses led to the definition
of no less than 50 accepted species within the genus, 17 of
which being medically relevant (Hickey et al., 2009; Colombo
et al., 2011). Therapeutic management of those infections may
also be challenging, since Trichosporon spp. exhibit an intrinsic
resistance to the echinocandins and a poor susceptibility to the
polyenes (Walsh et al., 1990).
To improve our knowledge of the epidemiology, diagnosis
and therapeutic management of those infections, we performed
a comprehensive review of the case reports and series published
between 1994 and 2015. In addition, we also analyzed studies of
in vitro susceptibility testing including a significant number of
Trichosporon isolates.
MATERIALS AND METHODS
Search Strategy and selection Criteria
We performed by the end of 2015 a systematic search in the
Pubmed database using the following key words: “Trichosporon,”
“trichosporonosis,” “invasive infection,” “sepsis,” “deep-seated
infection” and “fungemia.” To potentially detect species-specific
epidemiological traits, we limited our search after 1994, date
of the revised taxonomic classification. We only considered
proven invasive infections based on the EORTC-MSG definitions
(De Pauw et al., 2008). The cases of probable Trichosporon
pneumonia were also considered using the criteria proposed by
Colombo et al. (2011). Fungemia and infections involving two
non-contiguous organs were considered as disseminated. Data
on age, sex, underlying disease, immunological status, and the use
of intravenous catheter were collected for each case. Neutropenia
was defined as an absolute neutrophil count ≤0.5 × 109
neutrophils/L at the time of Trichosporon isolation. Antibiotic
therapy was taken into account as a possible predisposing factor
when administered for at least 1 week prior to the isolation
of Trichosporon. The antifungal therapies initiated either before
Trichosporon isolation or used for targeted treatment were
analyzed. Removal of intravenous catheter was also recorded. The
outcome was considered to be favorable if the patient survived or
if the infection was considered as cured at day 30 post-diagnosis.
Antifungal Susceptibility Testing Studies
We selected in vitro susceptibility testing studies that included
≥10 isolates for a given species and limited our analysis to
those having used a microdilution method. Only drugs with an
intravenous formulation were retained. Data on echinocandins
susceptibility were not included since Trichosporon exhibit
natural resistance to these drugs (Espinel-Ingroff, 2003). We
also compared antifungal susceptibility profile with the different
Trichosporon asahii genotypes.
Statistical Analysis
Comparisons between groups were performed using Fisher’s
exact or Chi-square tests when appropriate for the categorical
variables. For continuous non-parametric variables, comparisons
were made applying the Mann-Whitney U-test and the Kruskal-
Wallis one-way analysis of variance test. P-values of <0.05 were
considered to be statistically significant. Independent variable
found to be associated with death in a univariate analysis with
a p < 0.2, were included in a binary logistic regression analysis.
For this part, the level of statistical significance was set at p <
0.05. For each statistically significant factor, an odds ratio (OR)
and 95% confidence interval (CI) were computed Stata/IC 13.0
for Mac software (StataCorp, College Station, TX 77845, USA).
RESULTS
In a first instance, we found 537 cases of invasive Trichosporon
infection based on a PubMed search limited between 1994 and
2015. The number of reported cases of invasive Trichosporon
infections (ITI) grew significantly through the years, from 139
(25.8%) in the 1994–2004 to 398 (74.2%) between the 2005
and 2015 period (Chi-square test; p < 0.001). Three hundred
and thirty-four cases, mainly recorded in series, were excluded
because of insufficient data (Figure 1).
Among the 203 cases retained, 199 cases were proven
infection, whereas four were considered probable infection.
Excluding newborns (25 cases), the median age of those patients
was 41.6 years, but the range varied from 3 days of life to 85 years.
The sex ratio was calculated at 0.56.
For comparison analysis, the cases were clustered according to
the main underlying disease, e.g., homeopathy (n = 79; Grauer
et al., 1994; Higgins et al., 1994; Hsiao et al., 1994; Nasu et al.,
1994; Hung et al., 1995; Spánik et al., 1995; Itoh et al., 1996; Fanci
et al., 1997; Kataoka-Nishimura et al., 1998; Sklair-Levy et al.,
1998; Krcmery et al., 1999; Takamura et al., 1999; Erer et al.,
2000; Kim et al., 2001; Moretti-Branchini et al., 2001; Fournier
et al., 2002; Hadley et al., 2002; Meyer et al., 2002; Chang et al.,
2003; Marty et al., 2003; Bassetti et al., 2004; Chowdhary et al.,
2004; Viscomi et al., 2004; Antachopoulos et al., 2005; Chan-
Tack, 2005; Akagi et al., 2006; Ghiasian et al., 2006; Kendirli
et al., 2006; Koyanagi et al., 2006; Matsue et al., 2006; Meguro-
Hashimoto et al., 2006; Rodrigues et al., 2006; Hara et al., 2007;
Miura et al., 2007; Rieger et al., 2007; Bayramoglu et al., 2008;
Hosoki et al., 2008; Thibeault et al., 2008; Tsuji et al., 2008; Fekkar
et al., 2009; Walia et al., 2009; Gabriel et al., 2011; Kudo et al.,
2011; Hosokawa et al., 2012; Menezes et al., 2012; Chen et al.,
2014; Issarachaikul et al., 2014; Karapinar et al., 2014; Capoor
et al., 2015; Odero et al., 2015; Pérard et al., 2015; Tanyildiz
et al., 2015), other immunodeficiency conditions (n= 41; Canales
et al., 1998; Lascaux et al., 1998; Anuradha et al., 2000; Piwoz
et al., 2000; Ebright et al., 2001; Abliz et al., 2002; Chakrabarti
et al., 2002; Kahana et al., 2003; Nettles et al., 2003; Wynne et al.,
2004; Abdala et al., 2005; Gunn et al., 2006; Karabay et al., 2006;
Rodrigues et al., 2006; Biasoli et al., 2008; David et al., 2008; Gross
and Kan, 2008; Chagas-Neto et al., 2009; Lacasse and Cleveland,
2009; Servonnet et al., 2010; Fadhil et al., 2011; Macêdo et al.,
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FIGURE 1 | Flow diagram showing the cases retained after application of selection criteria. Trichosporon pullulans is now considered Gueomyces pullulans.
2011; Songcharoen et al., 2011; Basiri et al., 2012; Hirschi et al.,
2012; Ogura et al., 2012; Tsai et al., 2012; Chen et al., 2013;
Almeida Júnior et al., 2014; Yang et al., 2014; Chaitanya et al.,
2015; Nobrega de Almeida Júnior et al., 2015; Ozkaya-Parlakay
et al., 2016), miscellaneous (n = 58; De Saedeleer et al., 1994;
Lopes et al., 1994, 1995, 1997; Miralles et al., 1994, p. 10; Miró
et al., 1994; Sidarous et al., 1994; Still et al., 1994; Hajjeh and
Blumberg, 1995; Mathews and Prabhakar, 1995; Melez et al.,
1995; Chaumentin et al., 1996; Kouppari et al., 1997; Wang and
Lin, 1999; Cawley et al., 2000; Lo Passo et al., 2001; Mooty et al.,
2001; Wolf et al., 2001; Chitra et al., 2002; Kustimur et al., 2002;
Reddy et al., 2002; Crowther et al., 2003; Madariaga et al., 2003;
Spirn et al., 2003; Ramos et al., 2004; O’Gorman et al., 2006;
Rodrigues et al., 2006; Kim et al., 2007, 2008; Tian et al., 2007;
Fagundes Júnior et al., 2008; Jian et al., 2008; Chagas-Neto et al.,
2009; Hickey et al., 2009; Izumi et al., 2009; Shang et al., 2010;
Slocumb et al., 2010; Heslop et al., 2011; Tsai et al., 2011; Liao
et al., 2012; Padhi et al., 2014; Gonul et al., 2015; Kumar et al.,
2015; Negi et al., 2015; Zuo et al., 2015) and newborns (n = 25;
Yoss et al., 1997; Sweet and Reid, 1998; Gökahmetog˘lu et al., 2002;
Panagopoulou et al., 2002; Salazar and Campbell, 2002; Yildiran
et al., 2003; Maheshwari et al., 2004; Chagas-Neto et al., 2009;
Pereira et al., 2009; Vashishtha et al., 2012; Basu et al., 2015).
The main clinical characteristics of each group are summarized
in Table 1 and are detailed in Tables S1–S4.
Clinical Presentation of ITIs
The main clinical presentations of 203 cases of ITI are
summarized inTable 1. Among the 199 cases of proven infection,
dissemination was reported in 162 cases (79.8%) mainly due to
fungemia (n= 151, 93.2%). Blood was the unique site of isolation
in 90 cases. In other cases, the patients presentedmainly with skin
(n = 13), lungs (n = 17), skin and lungs (n = 14), liver and/or
spleen (n= 10), brain (n= 4), eyes (n= 3) involvement. In eleven
patients without fungemia, disseminated trichosporonosis was
diagnosed based on the involvement of the skin (n= 3), skin and
brain (n= 3), skin and lungs (n= 2), skin and digestive tract (n=
1), skin and liver (n = 1), heart valve and embolic material/skin
(n = 1). In the case of proven localized deep-seated infection
(n = 37), the following organs were predominantly involved:
peritoneum (n = 14), lower respiratory tract (n = 8), brain (n
= 3), eye (n = 3), esophagus (n = 3). Finally, four probable
Trichosporon pulmonary infections were retained.
Patients with Hematologic Disease (n = 79)
Acute myeloid leukemia (n = 40; 50.6%) was the most frequent
underlying disease in this group of patients, followed by acute
lymphoid leukemia (n = 17) and myelodysplasic syndrome (n
= 5). Sixty-seven of those patients (84.8%) were neutropenic
at the time of diagnosis of the Trichosporon infection. Eight
patients (10.1%) developed invasive trichosporonosis after a
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TABLE 1 | Characteristics of 203 cases of invasive Trichosporon infection according to the underlying conditions.
Groups of patients p-value
Hemopathies Other immunodeficiency conditions Newborns Miscellaneous
No. of cases (%) 79 (39) 41 (21) 25 (12) 58 (28)
Age (Mean ± SD) 39.5 ± 21.58 39.3 ± 22.2 NAa 46.8 ± 23.1 NSb
Sex ratio (F/M) 21/53 0.39 14/23 0.6 8/9 0.8 24/34 0.7 NS
AT THE TIME OF DIAGNOSIS (%)
Neutropenia 67 (85) 3 (8) 0 (0) 0 (0) <0.0001
CVCc 36 (46) 15(36) 12 (48) 19 (34) NS
Breakthrough infection 59 (74) 12 (27) 2 (8) 9(16) <0.0001
Previous antimicrobial therapy 65 (82) 24 (58) 24 (96) 39 (67) 0.005
CLINICAL PRESENTATION
Disseminated 79 (100) 25 (61) 25 (100) 33 (56) <0.0001
w/skin lesions 27 (34) 7 (28) 0 (0) 4 (12) 0.001
w/pulmonary lesions 33 (42) 6 (24) 1 (5) 3 (9) 0.0003
w/liver and/or spleen lesions 11 (14) 1 (4) 0 (0) 1 (3) 0.06
Localized deep-seated infections 0 (0) 16 (39) 0 (0) 25 (44) <0.0001
SPECIES
Trichosporon asahiid 32(40) 20 (48) 16 (64) 27 (46) NS
Trichosporon inkine 1 (1) 9 (22) 0 (0) 6 (11) 0.0003
Trichosporon mucoides/dermatisf,g 2 (2) 4 (9) 3 (12) 2 (3) NS
Other Speciesh 4 (5) 2 (5) 1 (4) 5 (10) NS
aNA, Not applicable.
bNS, not statistical.
cCentral venous catheter.
dTen, six, and ten isolates had IGS1, ITS1, and D1/D2 sequence-based identification, respectively.
eFour, three, and three isolates had IGS1, ITS1, and D1/D2 sequence-based identification, respectively.
fThe isolates identified as Trichosporon mucoides by phenotypical methods, which do not distinguish T. mucoides from T. dermatis in the absence of IGS1 sequence-based identification,
were merged into a single group (Gunn et al., 2006).
gTwo and one isolates had IGS1 and ITS1 sequence-based identification, respectively.
hTrichosporon asteroides (n = 5, four and had IGS1 and D1/D2 sequence-based identification, respectively) Trichosporon loubieri (n = 2, ITS1 sequence-based identification),
Trichosporon mycotoxinovorans (n = 2, ITS1 and D1/D2 sequence-based identification), Trichosporon laibachii (n = 1, ITS1 sequence-based identification), Trichosporon japonicum
(n = 1, ITS1 sequence-based identification), Trichosporon faecale (n = 1, IGS1 sequence-based identification). To delineate the species-specific peculiarities, the reports describing
infections attributed to the obsolete T. beigelli and T. cutaneum classifications were considered as caused by Trichosporon sp. Significant differences are indicated in bold.
bone marrow or a blood cord transplant, four (50%) during
the pre-engraftment period and under antifungal prophylaxis
[(amphotericin B (AMB) n= 2, caspofungin n= 1, voriconazole
n = 1)], four (50%) after severe graft-vs.-host disease and
under AMB prophylaxis. Thirty-six patients (45.5%) had at
least one central venous catheter (CVC) when the diagnosis
of ITI was established. All the cases corresponded to a
disseminated infection, 29 (36.7%) being isolated fungemia.
Organ involvement occurred in 50 patients (63.2%). In these
cases, pulmonary infection was the most common (n = 33;
41.7%), followed by skin lesions, which were observed in 27
cases (34.1%). On the whole group, an antimicrobial therapy
regimen prior to the episode of ITI was mentioned in 65
cases (82.2%). Fifty-nine patients (74.6%) had breakthrough
Trichosporon infection during treatment with different antifungal
drugs, including an echinocandin (n = 16), AMB (n = 25) or
azole derivatives (n= 18).
Other Immunodeficiency Disorders (n = 41)
In this group, trichosporonosis mainly occurred in patients
with solid organ transplantation (n = 13), solid tumors (n =
11) or autoimmune diseases (n = 8). Kidney transplantation
(n = 6) and lung cancer (n = 4) were the main underlying
conditions within the two predominant groups. A disseminated
infection was diagnosed in 25 cases (60.9%) and deep-organ
involvement was noticed in 12 cases (48%); skin and pulmonary
lesions being noticed in 7 and 6 cases, respectively. Isolated
pneumonia was diagnosed in three cases, and another three
cases had chronic lung infections presenting with pulmonary
abscesses or a penetrating chest wall mass. Twenty-four
(58.5%), 14 (34.1%), and 13 (31.7%) patients had received
antimicrobials, corticosteroids, and immunosuppressive drugs,
respectively, before the diagnosis of the invasive fungal infection.
Breakthrough infections were documented in 12 cases (29.2%).
Other Clinical Contexts (n = 58)
Finally, we found 58 cases of ITI in patients with miscellaneous
underlying conditions. Forty of them (68.9%) had received
antimicrobial therapy before the diagnosis of deed-seated
trichosporonosis. Among the 33 patients (56.8%) with
disseminated disease, 31 (93.9%) had severe baseline disease
[(heart failure or pulmonary embolism (n = 8; 24.2%), extensive
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burns (n = 5; 15.1%), polytrauma (n = 4; 12.1%)] and were
in intensive care units; 20 (60%) of them were reported
to have a CVC at the time of the infection. Additionally,
four (12.1%) had multiple surgeries before developing
disseminated trichosporonosis and another four patients
developed disseminated trichosporonosis during hemodialysis
(12.1%). Moreover, breakthrough infections occurred in nine
patients that had disseminated infection (27.2%).
Fourteen patients (24.1%) were diagnosed with deep-
seated post-operative infections, notably endocarditis after valve
replacement surgery (n = 5). Interestingly, the time between
the surgery and the occurrence of endocarditis was quite long,
ranging from 3 months to 8 years (median 3 years).
Twelve cases of Trichosporon peritonitis were recorded, and
11 (91.6%) of those cases complicated the course of continuous
ambulatory peritoneal dialysis.
Newborns (n = 25)
Twenty-five cases of ITI occurred in newborns. It is worth
noting that eleven cases were reported in two outbreaks from
Indian hospitals (Vashishtha et al., 2012; Basu et al., 2015).
Infections occurred between the third and the 84th day of life.
All of the infants except two were preterm at delivery, and 10
(40%) had extremely low birth weight (<1000 g). A previous
diagnosis of perinatal asphyxia or respiratory distress syndrome
was identified in 15 cases (60%), and all of the newborns but one
received previous antimicrobial therapy. Trichosporon infection
was disseminated in all cases either as isolated fungemia (n =
22; 88%) or associated with a deep-organ involvement (n = 3;
12%). Twelve infants (48%) had a CVC at the time of diagnosis of
the ITI.
Diagnostic Procedures
The diagnosis of ITI relied in all the cases on a positive
culture for Trichosporon from a clinical sample. In the 47
cases with a pathological examination of biopsy specimens, the
presence of arthroconidia was only mentioned in eight cases
(17%). Positive blood culture(s), as unique fungal isolation,
was the most common presentation (n = 100; 49.2%). In 69
cases (33.9%), there was no identification at the species level.
Species identification relied on molecular analysis of intergenic
spacer IGS1 (n = 22), ITS1 (n = 15) or D1/D2 domain of
the 26S regions of the rRNA gene (n = 15) (Table 2). In
other cases, there was either no information regarding the
method used for identification or the isolates were identified
using a commercial phenotypic method. Overall, Trichosporon
asahii (n = 95; 46.7%) was the main etiologic agent. Nine
additional species were identified: Trichosporon inkin (n = 16),
Trichosporon dermatis/mucoides (n= 11), and Trichosporon spp.
(n= 12). T. inkin was significantly less prevalent in patients with
homeopathy than in the rest of the population analyzed (p =
0.0003).
A positive serum Cryptococcus glucuronoxylomannan (GXM)
antigen assay was reported in 4 of 15 cases (26.6%) while β-D-
glucan (BDG) was detected in the serum of 9 among 11 tested
patients (81.8%).
Treatment and Outcome
Twenty-five different antifungal regimens were reported. AMB
was used in 111 cases, mainly as deoxycholate AMB (n =
89) and liposomal AMB (n = 18). Thirteen patients received
targeted treatment with echinocandins either in monotherapy
(n = 5) or combined with other antifungal (n = 8). All
those patients treated with echinocandin monotherapy for
disseminated infection died. Fluconazole was the azole drug the
most frequently used for the treatment of those infections (n
= 54). Combined antifungal therapy was commonly used (n
= 48; 24.2%). Twelve patients did not receive any antifungal
treatment, and 11 died. The unfavorable outcome rate was
calculated at 44.3%. Table 2 summarizes the impact of various
prognosis factors. In the univariate analysis, advanced age,
disseminated infection and neutropenia at the time of diagnosis
were associated with unfavorable outcome (p < 0.05). There
was also a similar trend for breakthrough infection and curative
therapy including an echinocandin drug (p < 0.1). By the
contrary, patients from group 2 and 3, and the use of either azole
or voriconazole in the therapeutic management were associated
with a better outcome. In the multivariate analysis, breakthrough
infection and azole-based therapy remained significant (p <
0.05) with odds ratio (IC95%) at 2.45 (1.05–5.97) and 0.17
(0.060–0.423), respectively. In neutropenic patients, we also
found the recovery of a normal neutrophils count as a favorable
prognosis factor with mortality rate at 15 vs. 92.31% (p =
0.001). Finally, in patients with hematologic disease, the use
of voriconazole in the curative regimen led to a significantly
better prognosis: favorable outcome rate at 73.6 vs. 41.8% (p =
0.016).
Antifungal Susceptibility Testing (AST)
Details from 19 studies having tested at least 10 Trichosporon
clinical isolates for a given species with a microdilution method
are presented inTables 3–8 (Arikan andHasçelik, 2002; Paphitou
et al., 2002; Ramos et al., 2004; Metin et al., 2005; Rodriguez-
Tudela et al., 2005; de Oliveira Silva et al., 2008; Chagas-Neto
et al., 2009; Taj-Aldeen et al., 2009; Thompson et al., 2009; Lemes
et al., 2010; Mekha et al., 2010; Guo et al., 2011; Sun et al., 2012;
Tsai et al., 2012; Hazirolan et al., 2013; Yang et al., 2013; Arabatzis
et al., 2014; Taverna et al., 2014; Montoya et al., 2015). Up to
now, there is no recommendation from the two main consortia
(EUCAST and CLSI) regarding the AST of Trichosporon. Thus,
it is important to note that the analyzed studies included some
variants in the application of the EUCAST or CLSI method: three
studies applied the EUCAST methodology including agitation at
350 rpm during incubation (Rodriguez-Tudela et al., 2005; de
Oliveira Silva et al., 2008; Taverna et al., 2014), and one of them
incubated the plates at 30◦C (Rodriguez-Tudela et al., 2005). Two
studies analyzed the CLSI method with MIC determination by
spectrophotometric reading (Taj-Aldeen et al., 2009; Tsai et al.,
2012). Interestingly, some works included comparisons of either
culture media (Tsai et al., 2012) or incubation times (24 vs.
48 h; Arikan and Hasçelik, 2002; Metin et al., 2005; Chagas-Neto
et al., 2009; Lemes et al., 2010; Tsai et al., 2012; Hazirolan et al.,
2013).
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TABLE 2 | Outcome predictors in patients with invasive Trichosporon infection according to univariate and multivariate analysis.
p-value
No. of patients Unfavorable outcome rate (%) Univariate analysis Multivariate analysis Odds Ratio (95% CI)
Sex NS
Female 66 42.42
Male 120 45.83
Age 0.042 0.08 1.02 (1.00–1.03)
Underlying diseasea NS
1 79 53.16 NS
2 41 36.59 0.087a
3 58 34.48 0.031a
4 25 52.00 NS
Speciesa NS
1 95 47.37 NS
2 15 31.25 NS
3 11 18.18 0.084a
4 81 46.91 NS
Breakthrough infection 0.053 0.049 2.45 (1.05–5.97)
Yes 84 52.38
No 119 38.66
Disseminated infection 0.001 0.070 2.62 (0.92–7.45)
Yes 162 50.62
No 41 19.51
Neutropenia 0.019 NS
Yes 70 55.71
No 133 38.35
Coinfection NS
Yes 19 47.37
No 184 44.02
Antifungal therapy 0.130 NS
Amphotericin-based
Yes 112 49.11
No 91 38.46
Echinocandin-based 0.073 NS
Yes 13 69.23
No 190 42.63
Azole based <0.001 <0.001 0.15 (0.06–0.42)b
Yes 101 28.71
No 102 67.78
Voriconazole based 0.035 NS
Yes 33 27.27
No 170 47.65
aComparison to the reference i.e., Trichosporon asahii for species and hematological patients for group of patients, respectively.
bThe odds ratio <1 is indicative of protection associated with the used of azole based therapy. Underlying disease: (1) Hemopathies, (2) other immunodeficiency conditions, (3)
miscellaneous diseases, (4) neonates. Species: (1) Trichosporon asahii, (2) Trichosporon inkin, (3) Trichosporon dermatis/mucoides, (4) Trichosporon beigelii and other species.
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TABLE 3 | In vitro susceptibility testing of amphotericin B against Trichosporon asahii clinical isolates.
(Author, year) No. of
tested
isolates
Country of
isolation
Method Modifications Incubation
time (h)
MICa range
(mg/L)
MIC
50
(mg/L)
MIC 90
(mg/L)
GMb
(mg/L)
Arikan and Hasçelik, 2002 43 Turkey CLSIc No 24 0.5–4 2 4 NDd
48 1–8 4 4 ND
Paphitou et al., 2002 24 USA CLSI No 24–48 0.25–8 0.5 ND ND
Rodriguez-Tudela et al., 2005 15* Spain,
Argentine
EUCASTe Agitation at 350
rpm, 30◦C
incubation
48 2–16 ND ND 5.2
Metin et al., 2005 13 Turkey CLSI No 24 0.03–2 0.06 1 ND
48 0.03–0.06 0.03 0.06 ND
de Oliveira Silva et al., 2008 10* Brazil EUCAST Agitation at 350
rpm
48 2–4.0 2 4 2.4
Chagas-Neto et al., 2009 15* Brazil CLSI No 24 0.5–2 ND ND 0.9
48 0.5–4 ND ND 1.4
Thompson et al., 2009 40 USA CLSI No 72 0.125–8 0.5 2 0.5
Taj-Aldeen et al., 2009 15* Qatar CLSI MIC reading with
spectrophotometer
48 2–≥16 8 ≥16 ND
Lemes et al., 2010 26 Brazil CLSI No 24 0.006–64 2 64 ND
48 0.006–64 4 64 ND
Mekha et al., 2010 101* Thailand CLSI No 24–48 0.125–16 0.5 2 0.7
Guo et al., 2011 35 China CLSI No 48 0.03–1 1 1 0.8
Sun et al., 2012 12* China CLSI MIC reading with
spectrophotometer
24–48 0.25–1 ND ND 0.5
Tsai et al., 2012 22* China CLSI MIC reading with
spectrophotometer
24 0.03–1 0.5 1 0.3
48 0.125–1 0.25 1 0.3
CLSI RPMI 2% glucose,
MIC reading with
spectrophotometer
24 0.25–1 0.5 1 0.5
48 0.5–16 1 2 1.17
EUCAST No 24–48 0.25–2 0.75 1 0.7
Yang et al., 2013 32* China CLSI No 48 ≤0.5–4 0.5 2 ND
Iturrieta-González et al., 2014 20 Brazil CLSI No 24–48 1–16 4 4 2.5
Arabatzis et al., 2014 37* Australia CLSI No 24–48 0.03–64 2 32 1.9
EUCAST No 24–48 0.06–32 2 16 1.9
Taverna et al., 2014 29* Argentina EUCAST No 24–48 0.25–4 ND ND 0.9
Montoya et al., 2015 Mexico CLSI No 24 0.5–16 2 4 1.84
aMIC, minimal inhibitory concentration.
bGM, Geometric mean.
cCLSI, Clinical Laboratory Standards Institute.
dND, not described.
eEUCAST, European Committee on Antimicrobial Susceptibility Testing.
*Studies having confirmed species identification using molecular analysis.
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TABLE 4 | In vitro susceptibility testing of fluconazole against Trichosporon asahii clinical isolates.
(Author, year) No. of
tested
isolates
Country of
isolation
Method Modifications Incubation
time (h)
MICa range
(mg/L)
MIC
50
(mg/L)
MIC 90
(mg/L)
GMb
(mg/L)
Arikan and Hasçelik, 2002 43 Turkey CLSIc No 24 0.5–4 1 4 NDd
48 1–8 2 8 ND
Paphitou et al., 2002 24 USA CLSI No 24–48 0.5–>64 2 ND ND
Rodriguez-Tudela et al., 2005 15* Spain,
Argentine
EUCASTe Agitation at 350
rpm, 30◦C
incubation
48 0.5–64 ND ND 7.6
Metin et al., 2005 13 Turkey CLSI No 24 0.5–1 0.25 1 ND
48 1–2 0.5 2 ND
de Oliveira Silva et al., 2008 10* Brazil EUCAST Agitation at 350 rpm 48 16–32 16 32 17.1
Chagas-Neto et al., 2009 15* Brazil CLSI No 24 0.25–2 ND ND 0.8
48 0.25–8 ND ND 1.3
Thompson et al., 2009 40 USA CLSI No 72 0.25–>64 1 2 1.2
Taj-Aldeen et al., 2009 15* Qatar CLSI MIC reading with
spectrophotometer
48 0.25–64 4 8 ND
Lemes et al., 2010 26 Brazil CLSI No 24 0.5–8 2 8 ND
48 0.5–16 4 8 ND
Mekha et al., 2010 101* Thailand CLSI No 24–48 4–64 8 64 9.6
Guo et al., 2011 35 China CLSI No 48 1–32 2 8 2
Sun et al., 2012 12* China CLSI MIC reading with
spectrophotometer
24–48 0.5–4 ND ND 1.2
Tsai et al., 2012 22* China CLSI MIC reading with
spectrophotometer
24 0.125–16 1 4 1.3
48 0.125–16 2 4 1.7
CLSI RPMI 2% glucose,
MIC reading with
spectrophotometer
24 0.125–16 1 2 1
48 0.5–16 2 4 2.2
EUCAST No 24–48 0.125–4 1 4 1.2
Yang et al., 2013 32* China CLSI No 48 ≤2–16 2 4 ND
Hazirolan et al., 2013 90 Turkey CLSI No 24 0.125–8 1 4 1.5
48 0.5–16 4 8 2.2
Iturrieta-González et al., 2014 20 Brazil CLSI No 24–48 2–4 4 4 3.1
Arabatzis et al., 2014 37* Australia CLSI No 24–48 1.0–64 8 64 8.5
EUCAST No 24–48 0.5–64 8 64 7.8
Taverna et al., 2014 29* Argentina EUCAST No 24–48 1–64 ND ND 7.63
Montoya et al., 2015 Mexico CLSI No 48 0.125–16 0.5 1 0.78
aMIC, minimal inhibitory concentration.
bGM, Geometric mean.
cCLSI, Clinical Laboratory Standards Institute.
dND, not described.
eEUCAST, European Committee on Antimicrobial Susceptibility Testing.
*Studies having confirmed species identification using molecular analysis.
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TABLE 5 | In vitro susceptibility testing of voriconazole against Trichosporon asahii clinical isolates.
(Author, year) No. of
tested
isolates
Country of
isolation
Method Modifications Incubation
time (h)
MICa range
(mg/L)
MIC
50
(mg/L)
MIC 90
(mg/L)
GMb
(mg/L)
Rodriguez-Tudela et al.,
2005
15* Spain,
Argentine
EUCASTc Agitation at 350
rpm, 30◦C
incubation
48 0.03–8 NDd ND 0.3
Chagas-Neto et al.,
2009
15* Brazil CLSIe No 24 0.03–0.06 ND ND 0.03
48 0.03–0.06 ND ND 0.03
Thompson et al., 2009 40 USA CLSI No 72 0.03–0.12 0.03 0.06 0.03
Taj-Aldeen et al., 2009 15* Qatar CLSI MIC reading with
spectrophotometer
48 0.016–2 0.12 0.25 ND
Lemes et al., 2010 26 Brazil CLSI No 24 0.03–4 0.5 1 ND
48 0.03–4 1 2 ND
Mekha et al., 2010 101* Thailand CLSI No 24–48 0.06–0.25 0.12 0.25 0.09
Guo et al., 2011 35 China CLSI No 48 0.03–1 0.06 0.5 0.08
Sun et al., 2012 12* China CLSI MIC reading with
spectrophotometer
24–48 0.03–0.12 ND ND 0.06
Tsai et al., 2012 22* China CLSI MIC reading with
spectrophotometer
24 0.016–2 0.06 0.5 0.03
48 0.016–8 0.03 0.06 0.03
CLSI RPMI 2% glucose,
MIC reading with
spectrophotometer
24 0.125–4 0.5 2 0.5
48 0.25–8 0.5 4 0.6
EUCAST No 24–48 0.125–1 0.5 1 0.4
Yang et al., 2013 32* China CLSI No 48 ≤0.03–8 0.03 0.06 ND
Arabatzis et al., 2014 37* Australia CLSI No 24–48 0.064–32 1 32 1.07
EUCAST No 24–48 0.064–32 1 32 1.06
Taverna et al., 2014 29* Argentina EUCAST No 24–48 0.03–0.5 ND ND 0.12
Iturrieta-González et al.,
2014
20 Brazil CLSI No 24–48 0.03–0.06 0.03 0.06 0.04
Montoya et al., 2015 Mexico CLSI No 48 0.03–1 0.03 0.03 0.04
aMIC, minimal inhibitory concentration.
bGM, Geometric mean.
cEUCAST, European Committee on Antimicrobial Susceptibility Testing.
dND, not described.
eCLSI, Clinical Laboratory Standards Institute.
*Studies having confirmed species identification using molecular analysis.
AST of Trichosporon asahii Isolates
By far, T. asahii was the most studied species (636 isolates
evaluated amongst 698). The distribution of minimal
inhibitory concentrations (MICs) against AMB was quite
heterogeneous (Table 3), with MIC50s (concentration that
inhibits the growth of 50% of the tested isolates), MIC90s
(concentration that inhibits the growth of 90% of the tested
isolates) and MIC geometric means (GMs) ranging between
0.03–8, 1–64, and 0.26–5.2mg/L, respectively. Higher MIC
values for AMB were described notably in two studies
that applied the EUCAST methodology with agitation
during incubation (isolates from Spain, Argentina, and
Brazil; Rodriguez-Tudela et al., 2005; de Oliveira Silva et al.,
2008).
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TABLE 6 | In vitro susceptibility testing of posaconazole and isavuconazole against Trichosporon asahii clinical isolates.
(Author, year) No. of
tested
isolates
Country of
isolation
Method Antifungal Incubation
time
MICa range
(mg/L)
MIC 50
(mg/L)
MIC 90
(mg/L)
GMb
(mg/L)
Paphitou et al.,
2002
24 USA CLSIc Posaconazole 24–48 0.06–>16 0.125 NDd ND
Thompson et al.,
2009
40 USA CLSI Posaconazole 72 0.06–0.5 0.25 0.25 0.2
Taj-Aldeen et al.,
2009
15* Qatar CLSI, MIC reading
with
spectrophotometer
Posacanazole 48 0.06–0.25 0.25 0.25 ND
Isavuconazole 48 0.008–0.5 0.125 0.125 ND
Hazirolan et al.,
2013
90 Turkey CLSI Posaconazole 24 ≤0.015–1 0.125 0.5 0.1
48 0.06–1 0.25 0.5 0.2
Isavuconazole 24 ≤0.015–0.5 0.03 0.25 0.07
48 ≤0.015–0.5 0.125 0.25 0.1
Arabatzis et al.,
2014
37* Australia CLSI Posaconazole 24–48 0.03–16 1 4 0.9
EUCASTe Posacanazole 24–48 0.06–32 1 4 1.4
Taverna et al., 2014 29* Argentina EUCAST Posaconazole 24–48 0.015–1 ND ND 0.2
Montoya et al.,
2015
39 Mexico CLSI Posaconazole 48 0.03–0.5 0.06 0.25 0.08
aMIC, minimal inhibitory concentration.
bGM, Geometric mean.
cCLSI, Clinical Laboratory Standards Institute.
dND, not described.
eEUCAST, European Committee on Antimicrobial Susceptibility Testing.
*Studies having confirmed species identification using molecular analysis.
TABLE 7 | In vitro susceptibility testing against Trichosporon inkin clinical isolates.
(Author, year) No. of tested
isolates
Country of
isolation
Method Incubation
time (h)
Antifungal MICa range
(mg/L)
MIC 50
(mg/L)
MIC 90
(mg/L)
GMb
(mg/L)
Ramos et al., 2004 11 Spain EUCASTc, Agitation at
350 rpm, 30◦C
incubation
48 AMBd 0.006–1 0.25 1 0.3
Fluconazole 1.0–32 2 8 2.7
Voriconazole 0.03–0.5 0.12 0.5 0.11
Rodriguez-Tudela
et al., 2005
11* Spain,
Argentine
EUCAST, Agitation at
350 rpm, 30◦C
incubation
48 AMB 0.03–1 ND ND 0.2
Fluconazole 0.5–4 ND ND 2
Voriconazole 0.03–2 ND ND 0.12
aMIC, minimal inhibitory concentration.
bGM, Geometric mean.
cEUCAST= European Committee on Antimicrobial Susceptibility Testing.
dAMB, amphotericin B.
*Studies having confirmed species identification using molecular analysis.
Among the azole compounds, fluconazole was the compound
most extensively analyzed (Table 4). MIC distribution of
fluconazole was also heterogeneous, with MIC50s, MIC90s and
MIC geometric means (GMs) ranging between 0.5–16, 1–64,
and 0.8–17.1mg/L, respectively. Again, higher MIC values were
described notably in three studies that applied the EUCAST
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TABLE 8 | In vitro susceptibility testing against Trichosporon mucoides/dermatis clinical isolates.
(Author, year) No. of tested
isolates
Country of
isolation
Method Antifungal Incubation
time (h)
MICa
range
(mg/L)
MIC 50
(mg/L)
MIC 90
(mg/L)
GMb
(mg/L)
Rodriguez-
Tudela et al.,
2005
16* Spain,
Argentine
EUCASTc, Agitation at
350 rpm, 30◦C
incubation
AMBd 48 0.03–1 ND ND 0.2
Fluconazole 48 0.5–4 ND ND 2
Voriconazole 48 0.03–2 ND ND 0.12
Metin et al.,
2005
14 Turkey CLSIe AMB 24 0.03–4 0.03 0.25 ND
48 0.03–4 0.06 2 ND
Fluconazole 24 0.125–32 1 2 ND
48 0.125–64 2 8 ND
Voriconazole 24 0.03–0.5 0.03 0.03 ND
48 0.3–0.5 0.03 0.25 ND
Thompson et al.,
2009
10 USA CLSI AMB 72 0.125–8 0.5 2 0.5
Fluconazole 72 0.12–1 0.12 1 0.25
Voriconazole 72 0.03–0.06 0.03 0.06 0.03
aMIC, minimal inhibitory concentration.
bGM, Geometric mean.
cEUCAST, European Committee on Antimicrobial Susceptibility Testing.
dAMB, amphotericin B.
eCLSI, Clinical and Laboratory Standards Institute.
*Studies having confirmed species identification using molecular analysis.
methodology with agitation during incubation (isolates from
Spain, Argentina, and Brazil; Rodriguez-Tudela et al., 2005; de
Oliveira Silva et al., 2008; Taverna et al., 2014). Lowest MICs were
observed for the last generation of triazoles, i.e., voriconazole
(Table 5), and indeed for isavuconazole and posaconazole
(Table 6).
Interestingly, while individual studies did not find any
correlation between genotype and in vitro susceptibility, when
merging the data available from 4 well-designed studies
(Rodriguez-Tudela et al., 2007; Guo et al., 2011; Yang et al., 2013;
Arabatzis et al., 2014), we noted that genotype 3 strains may
exhibit higherMICs to voriconazole than genotype 1 strains:MIC
GM 0.12 vs. 0.49mg/L, p= 0.04, whereas theMIC values of AMB
(MIC GM 1.9 vs. 1.2, p = 0.2) and fluconazole (MIC GM 5.2 vs.
5.6, p= 0.7) were similar for both genotypes.
Of note, the reading at 48 h instead of 24 h only slightly
increases the MICS by one dilution and the results obtained
either using the CLSI or the EUCAST method are quite
similar with the possible exception of voriconazole for which
higher MICs were observed using the EUCAST method
in one of two studies (Tsai et al., 2012; Arabatzis et al.,
2014).
AST of Trichosporon inkin, Trichosporon
Mucoides/Dermatis Isolates
In comparison to T. asahii, a much narrow MICs distribution
for AMB was described for both species, with MIC GM ranging
between 0.21–0.29mg/L for T. inkin (Table 7) and 0.61–0.69
mg/L for T. mucoides/dermatis (Table 8). Conversely, a wide
range of MIC GMs of fluconazole against T. mucoides/dermatis
has been reported, ranging from 0.25 to 7mg/L. Two of
three studies described higher fluconazole MICs of T.
mucoides/dermatis isolates in comparison to the MICs of T.
asahii isolates (Metin et al., 2005; Rodriguez-Tudela et al., 2005).
The MIC GM of fluconazole against T. inkin isolates ranged
from 2 to 2.74mg/L. Rodriguez-Tudella and collaborators
described lower MICs of fluconazole against T. inkin isolates
in comparison to T. asahii and T. mucoides/dermatis isolates
(Rodriguez-Tudela et al., 2005). Voriconazole exhibited the
lowest MICs against both T. inkin and T. mucoides/dermatis,
with MIC GMs ranging from 0.11 to 0.12 for T. inkin and 0.03 to
0.25 for T. mucoides/dermatis.
DISCUSSION
Trichosporon emerged as a pathogen in the 70–80’s, mainly for
neutropenic patients (Gold et al., 1981; Walsh et al., 1986).
Despite the lack of data providing the real incidence of ITI at
this time, published series supported the fact that Trichosporon
was the second most frequent agent responsible for fungemia
in this population (Leblond et al., 1986; Anaissie et al., 1992).
Based on clinical and experimental data, it was then shown
that azoles had a significant activity against Trichosporon, while
being less toxic that the standard at that time treatment,
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amphotericin B (Anaissie et al., 1992). This and the wider
use of azole drugs either as prophylaxis or empirical therapy
probably explain the decreasing concern regarding ITI in 90’s.
Between 1989 and 2002, an estimated incidence, of 81 cases per
100,000 admissions and 3 per 100,000 admissions were reported
in patients with hematologic malignancies and patients with
solid tumors, respectively (Kontoyiannis et al., 2004). Similarly,
in an Italian multicentric study conducted in 15 hematology
departments between 1983 and 2002, an incidence of 0.4% was
observed in patients with acute leukemia (Girmenia et al., 2005).
However, more recently, the MD Anderson Cancer Center (TX,
USA) demonstrated an increase in the incidence of invasive
yeast infections not due to Candida or Cryptococcus, of which
20% were Trichosporon, from 1.8 to 2.35 cases per 100,000
patient-days between the periods 1998–2004 and 2005–2010
(Chitasombat et al., 2012). Again this may reflect the change
in the antifungal stewardship for neutropenic patients. Indeed,
echinocandin drugs, which emerged as valuable options of choice
for either prophylaxis, pre-emptive or empirical therapy, have no
effect on Trichosporon (Asada et al., 2006; Matsue et al., 2006;
Hiramatsu et al., 2008; Suzuki et al., 2010; Park et al., 2014;
Nachbaur et al., 2015). Our review supports this re-emergence
with a significant increase of reported cases in the second part of
the 2000s decade.
In accordance with previous studies, we found that
hematological diseases (38.9% of the cases), mainly acute
leukemia, remain the most common underlying condition of
ITI, however, with a much smaller percentage than previous
reported (Girmenia et al., 2005). Eighty-five percent of the
patients with hematological diseases were neutropenic at the
time of ITI diagnosis, supporting the fact that neutrophil
cells are, as for candidiasis and aspergillosis, essential in the
prevention of ITI. The disruption of the mucosal barrier owing
to chemotherapy-induced mucositis may also contribute to
invasion of the yeast cells. This, combined with the modification
of the digestive flora due to previous antibiotic therapies,
observed in 58–96% of the cases according to the patients’
group, may favor the translocation of yeasts from the digestive
tract to the blood vessels. However, our study also revealed
that not only patients with hematological malignancy are
now concerned, as we showed that other conditions mainly
related to severe baseline diseases (e.g., SOT, auto-immune
diseases, solid tumor, preterm birth, extensive skin lesions
such as burns, or pemphigus) and invasive procedures (e.g.,
CVC, prosthetic heart valves), may also favor the occurrence
of ITI.
The origin of Trichosporon infections, notably post-operative
ones, is uncertain. Indeed, Trichosporon has been isolated from
the hospital environment (Fanfair et al., 2013), but is also
considered a commensal of the digestive tract and may colonize
the skin of healthy patients (Colombo et al., 2011; Zhang et al.,
2011; Cho et al., 2015). In neonates, it is likely that the increasing
permissiveness of the natural barriers, mainly the skin and the
digestive mucosa, may favor the translocation of any yeast types,
including Trichosporon, which has also been isolated from the
skin of preterm infants (Kaufman et al., 2001). In addition, total
parenteral nutrition, frequently used in this context, may have
been the source of an outbreak ofT. asahii bloodstream infections
(Vashishtha et al., 2012).
In any case, the clinical features of invasive trichosporonosis
were not specific. The persistence of fever during ongoing
treatment with AMB or echinocandins may be more supportive
(Colombo et al., 2011). Dissemination is a common feature,
particularly in patients with homeopathy and newborns (100%
of the cases). While difficult to interpret when solely based
on culture results, pulmonary lesions are frequently reported
as diffuse nodules, lobar pneumonia, reticulonodular infiltrates,
or mass-like lesions (Akagi et al., 2006; Kendirli et al., 2006).
Positive culture for Trichosporon from respiratory tract samples,
notably when repeated should always be interpreted with caution
in patients with risk factors. Skin lesions were the second
most common tissue involvement and warrant the addition
of trichosporonosis to the list, which included candidiasis and
fusariosis, as a cause of skin lesions during febrile neutropenia.
The cutaneous lesions, mainly located in the lower extremities,
the trunk and the face, are typically hemorrhagic macular or
maculopapular, and differ in subtle way from those of Candida
that tend to be punctate, pseudopustular (necrotic epicenter)
with a rim of erythema (Nucci et al., 1992; Higgins et al., 1994;
Miura et al., 2007).
The diagnosis of ITI always relies on the isolation of a yeast-
like organism from a clinical specimen further identified as
Trichosporon. Direct examination of clinical specimens rarely
contributed to diagnosis as it rarely demonstrated arthroconidia
in samples. It is remarkable than about a third of the isolates had
not been identified at the species level. Phenotypic approaches
have been shown to be poorly efficient and direct sequencing
of the IGS1 region of the ribosomal DNA is now considered
the reference method for species identification of Trichosporon
isolates (Sugita et al., 2002). MALDI-TOF mass spectrometry,
which has recently been shown to be a valuable alternative
for routine identification (de Almeida Júnior et al., 2014),
should help at reducing the part of non- or uncertainly-
identified isolates in order to test more in depth, possible species-
specific epidemiological traits, and clinical scenarios. Therapeutic
adaptation may also be required according to the causative
species.
Unfortunately, serum markers are either unsatisfactory or
have not been evaluated in depth for the diagnosis of ITI.
Although, it is well-known that Trichosporon shares some
antigenic properties with Cryptococcus neoformans (Campbell
et al., 1985), a cross reaction with the cryptococcal GXM antigen
assay was only found in 26% of the tested cases; a negative
assay thus does not rule out the diagnosis. BGD assays may
be more interesting with nine positive results among 11 sera
tested. Similarly, in a case series study, 12 out of 25 patients with
Trichosporon fungemia have been reported with significant levels
of BDG (Suzuki et al., 2010). While the use of molecular tools,
not commercially available, is more anecdotal, a study reported
a good performance of a real-time PCR assay to detect T. asahii
DNA from the blood samples (Tsuji et al., 2008).
T. asahii was shown to be associated with a poor prognosis
what may be due in part to its lower susceptibility to antifungal
drugs (Pfaller et al., 2009). Nevertheless, neither the CLSI
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nor the EUCAST consortium has proposed a standardized
procedure for AST of Trichosporon. Zaragoza et al. analyzed
different parameters for optimal growth of nonfermentative
yeasts, including some Trichosporon strains, for AST (Zaragoza
et al., 2011), and showed that the use of yeast nitrogen base
medium (YNB), agitation and incubation at 30◦C resulted in a
better growth and a more reliable and stable measurement of
the MIC values. However, whatever was the conditions used they
found an excellent agreement between themethods when reading
the MICs after 48 h of incubation (Zaragoza et al., 2011).
Despite the lack of defined clinical breakpoints, the constantly
elevated MICs against the echinocandins support natural
resistance to this antifungal class (Colombo et al., 2011).
Similarly, because the minimal fungicidal concentrations of
polyenes have been shown to be 20-fold greater than the
minimal inhibitory concentration, the Trichosporon genus was
also considered naturally resistant to these drugs, notably AMB
(Walsh et al., 1990). However, after the taxonomic reevaluation, it
has been shown thatT. asahii clearly exhibits higherMICs against
AMB compared to other species, such as T. mucoides/dermatis
and T. inkin (Rodriguez-Tudela et al., 2005; Tsai et al., 2012).
On the contrary, T. mucoides/dermatis appears to be more
resistant in vitro to fluconazole compared to other species
(Metin et al., 2005; Rodriguez-Tudela et al., 2005). Nevertheless,
whatever is the species considered, voriconazole, posaconazole,
and isavuconazole offer a better in vitro efficacy compared to
fluconazole, even if some T. asahii isolates belonging to genotype
3 with reduced susceptibility to voriconazole has been described
(Yang et al., 2013; Arabatzis et al., 2014). The heterogeneity
of population structure of T. asahii may also explain the great
variability in MICs found in this species against the different
antifungals evaluated.
To the best of our knowledge, there is no study designed
specifically to compare different antifungal regimens in the
management of those infections. The lack of antifungal treatment
led to a fatal outcome almost constantly. In our review, the
overall unfavorable outcome rate was at 44.3%. This rate
was quite similar to that reported in a US Cancer Center
(50%) but slightly lower than that found in the study by
Girmenia et al. (64.7%), where AMB was the main (76.5%)
drug used for treatment. Indeed, our review suggests that
azole-based therapy may be superior to echinocandin- or
amphotericin-based therapies. Similar findings were reported
in a retrospective study of 33 patients with hematological
malignancy: the mortality rate was 63% with azole-based therapy
vs. 100% in the absence of any azole drug in the therapeutic
regimen (p = 0.031; Suzuki et al., 2010). In our study, the
use of voriconazole significantly improved the prognosis of
patients with hematological malignancy supporting the recent
recommendations proposed by the ESCMID (Arendrup et al.,
2014).
CONCLUSIONS
Although, hematologic malignancies are the main underlying
diseases, invasive Trichosporon infection may also occur in
other contexts of immunosuppression, in newborns and in
various conditions of debilitating diseases, with different clinical
presentations. Due to the natural resistance to echinocandins and
polyenes of Trichosporon, breakthrough infections are common.
Bloodstream infection sometimes combined with pneumonia
and/or skin lesions are the most common clinical feature
in patients with hematologic malignancies. T. asahii is the
predominant causative species and is associated with a poor
prognosis, possibly linked to its reduce sensitivity to some
azole drugs. Nevertheless, first line therapy should rely on
azole derivatives and particularly voriconazole, which exhibits
the best in vitro activity against Trichosporon species and
significantly leads to a better outcome in patients with underlying
homeopathy.
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